Close Menu

NEW YORK — Cancer Genetics on Thursday posted a nearly 24 percent year-over-year decline in revenues for the third quarter as the SARS-CoV-2 pandemic impacted its customers' R&D operations.

For the three-month period ended September 30, Cancer Genetics' revenues fell to $1.6 million from $2.1 million a year earlier as customers for its drug-discovery and preclinical oncology services experienced shifted their resources to SARS-CoV-2 initiatives and their scientific and discovery teams began working remotely.          

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Sponsored by

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Sponsored by

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.